Funded Startups in Liege
Five of the seven entries list undisclosed/unknown series labels, but disclosed round sizes show a sharp concentration at the top end: EyeD Pharma raised $…
Five of the seven entries list undisclosed/unknown series labels, but disclosed round sizes show a sharp concentration at the top end: EyeD Pharma raised $51M on 2021-12-24, an outlier compared with the next-largest disclosed amounts of $11M (Bio-Sourcing, 2024-09-24) and $7M (Amyl Therapeutics, 2023-11-07). The other disclosed rounds cluster between $1M and $3M, including AlphacomSolution at $1M (2024-03-31) and Hedera-22 at $2M (2024-08-14).
Biotechnology is the most frequent sector (four of seven entries: Bio-Sourcing, Hedera-22, Amyl Therapeutics, EyeD Pharma), and the geographic pattern is consistent within Liège (all seven rows are in Liège, Liege, Belgium). Temporally, the list spans from 2020-10-23 (Musimap) to 2024-09-24 (Bio-Sourcing), with three biotech/health-related rounds landing in 2024 alone (Bio-Sourcing, Hedera-22, MYOCENE).
Most recent rounds
7 shownRelated listings
Frequently asked
Which disclosed round is the size outlier in this Liège list, and how far above the rest is it?
EyeD Pharma’s $51M round on 2021-12-24 is the only disclosed amount above $50M and it dwarfs the next-largest disclosed amounts of $11M (Bio-Sourcing, 2024-09-24) and $7M (Amyl Therapeutics, 2023-11-07). Most other disclosed rounds sit between $1M and $3M, such as AlphacomSolution at $1M (2024-03-31) and Hedera-22 at $2M (2024-08-14).
Are there sector concentrations, or is the mix evenly distributed across categories?
Biotechnology is over-represented at four of seven entries (Bio-Sourcing on 2024-09-24; Hedera-22 on 2024-08-14; Amyl Therapeutics on 2023-11-07; EyeD Pharma on 2021-12-24). AI appears twice (AlphacomSolution on 2024-03-31 at $1M; Musimap on 2020-10-23 at $700K), while Health Care appears once (MYOCENE on 2024-06-18 at $3M).
Do multiple rounds fall into a tight date window near the most recent closings?
Yes, the 2024 cluster is noticeable: Bio-Sourcing ($11M, 2024-09-24), Hedera-22 ($2M, 2024-08-14), MYOCENE ($3M, 2024-06-18), and AlphacomSolution ($1M, 2024-03-31) all close within 2024. In contrast, only two entries fall outside 2024 and are much earlier (EyeD Pharma in 2021 and Musimap in 2020).
What stage labeling pattern shows up across these seven rows?
Five of the seven entries use a 'Series Unknown' style classification (Bio-Sourcing, Hedera-22, Amyl Therapeutics, EyeD Pharma, and Hedera-22’s category label format includes 'Venture - Series Unknown' for EyeD Pharma). The explicit stage labels shown elsewhere are Seed for MYOCENE (2024-06-18 at $3M) and a blank series field for AlphacomSolution (2024-03-31 at $1M) and Musimap (2020-10-23 at $700K).
Which entries are the smallest disclosed rounds, and do they share a theme?
The smallest disclosed amount is Musimap at $700K (2020-10-23), followed by AlphacomSolution at $1M (2024-03-31). Both are categorized under AI (Musimap and AlphacomSolution), while the lowest biotech/health disclosed rounds are higher (Hedera-22 at $2M and MYOCENE at $3M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.